| 產(chǎn)品編號 | bs-0091R-FITC |
| 英文名稱1 | Rabbit Anti-CA125/FITC Conjugated antibody |
| 中文名稱 | FITC標記的卵巢癌抗原抗體 |
| 別 名 | CA 125; CA125; CA-125; CA125 ovarian cancer antigen; Cancer antigen 125; FLJ14303; MUC16_HUMAN; MUC 16; MUC16; Mucin 16; MUC-16; Mucin 16 cell surface associated; Mucin16; Ovarian cancer related tumor marker CA125; Ovarian carcinoma antigen CA125; Ovarian cancer-related tumor marker CA125. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 信號轉(zhuǎn)導(dǎo) 細胞類型標志物 細胞骨架 腫瘤細胞生物標志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 200kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CA125 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: MUC16 (CA125) is a serum marker that is used routinely in gynecologic practice to monitor patients with ovarian cancer. It is a mullerian duct differentiation antigen that is overexpressed in epithelial ovarian cancer cells and secreted into the blood, although its expression is not entirely confined to ovarian cancer. Most biochemical studies have concluded that MUC16 is a high molecular mass glycoprotein, although estimates of its size range from 200 to 2000 kDa with smaller “subunits” being described by some investigators. Function: Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Subunit: Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Secreted, extracellular space. Note=May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain. Tissue Specificity: Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas. Post-translational modifications: Heavily O-glycosylated; expresses both type 1 and type 2 core glycans. Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans. May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space. May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts. Similarity: Contains 2 ANK repeats. Contains 56 SEA domains. Database links: Entrez Gene: 94025 Human SwissProt: Q8WXI7 Human Unigene: 432676 Human
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CA125是與卵巢癌細胞相關(guān)的膜表面糖蛋白。在正常情況下卵巢細胞中無CA125抗原，但在經(jīng)期和孕期婦女的卵巢中發(fā)現(xiàn)存在由此種抗原。 該蛋白是上皮性卵巢癌尤其是漿液性腺癌的主要標記，也可用于其他惡性腫瘤的研究，如：乳腺癌、胰腺癌、肝癌和消化系統(tǒng)的腫瘤等。 |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
